Tuesday, September 27, 2022

Growth Hormone Deficiency Market 2022 Estimation and Forecasts up to 2027

 Growth Hormone Deficiency Market

Growth hormone deficiency also called pituitary dwarfism or simply dwarfism, refers to a condition resulting from inadequate quantities of growth hormone in the body. Kids with GHD have weirdly short stature with usual body proportions. According to the MRFR reports, the global market for growth hormone deficiency is projected to acquire a market size of USD 5,243.3 Million by 2027 with a healthy CAGR of 4.20%.

The growth of the GHD market is being driven by the factors such as a rise in growth hormone used to prevent aging, an increase in neuropsychiatric cases, an increase in growth hormone deficiency disorders, and the rise in awareness of the treatment procedure. However, the fluctuations in drug productivity in pharmaceutical companies and the high cost of the treatment may have an adverse impact on the market growth.

Competitive Analysis

The global market for growth hormone deficiency is flooded with a wide number of players spread worldwide. The players in the market are focusing more and more on the implementation of new strategies and policies such as collaborations, expansions, acquisitions, joint ventures, and a rising number of FDA approvals. The list of leading players in the growth hormone deficiency market includes companies such as Pfizer, Merck KGaA, Novartis AG, Eli Lily and Company, Novo Nordisk A/S, and several others.

Segment Analysis

The global Growth Hormone Deficiency Market is divided into several segments based on brand, application, distribution channel, route of administration, and region.

By brand, the market is split into Omnitrope, Saizen, Humatrope, Genotropin, Norditropin, and others.

By application, the growth hormone deficiency market is divided into prader willi syndrome, adult growth hormone deficiency, turner syndrome, small for gestational age, idiopathic short stature, and pediatric growth hormone deficiency.

Based on the route of administration, the market is split into intravenous, intramuscular, and subcutaneous.

The market is split into E-commerce, clinics, retail pharmacies, and hospital pharmacies by distribution channel.

Regional Analysis

The global market for growth hormone deficiency is studied across five major regions: Asia-Pacific, Europe, North America, South America, and the Middle East & Africa.

The North American regional market for growth hormone deficiency held the top position in the global market in 2019 and is likely to maintain dominance over the review timeframe. The growth of the regional market is attributed to the factors such as growing awareness regarding the efficacy of the hormone in short stature, expanding applications of the hormone, and the rising prevalence of growth hormone deficiency. The US and Canada are two major markets in the region.

The European regional market for growth hormone deficiency is likely to exhibit substantial growth over the review timeframe. The region is mainly divided into two major parts, such as Western Europe and Eastern Europe. The Western European region is comprised of Spain, Italy, France, the UK, and Germany. The market is projected to secure the second position in the growth hormone deficiency market over the assessment timeframe. The regional market's growth is being driven by the factors such as growing government expenditure for the healthcare sector, rising shift towards growth hormones in the treatment of Idiopathic Short Stature (ISS), and the increasing occurrences of growth hormone deficiencies.

The Asia-Pacific regional growth hormone deficiency market is projected to record the highest growth rate over the forecasted era. The growing healthcare expenditure is mainly propelling the growth of the regional market. Additionally, the rising investments by market players in the region, given the increasing demand, are also projected to catalyze the regional market's growth.

The Middle East & African regional market is expected to significantly grow over the assessment timeframe due to the growing patient pool, rising investments by major market players, and increasing healthcare expenditure.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013v

Cell Lysis and Disruption Market Shares Analysis, Key Development Strategies and Forecasts Till 2027

 Market Forecast

Registering a CAGR of 8.6%, the Global Cell Lysis & Disruption Market is expected to reach USD 5.7 Billion in by 2025.

 The expanding biotechnology and biopharmaceutical sector are driving the growth of this market. For instance, firms in the U.S. firms perform extensive R&D in pharmaceuticals which is approximately USD 75 billion. 

The market is dominated by numerous established players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in June 2018, Thermo Fisher Scientific acquired Gatan, Inc. from Roper Technologies for approximately USD 925 million.

Market Influencers

The rising focus on personalized medicine would directly drive the growth of the global cell lysis & disruption market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to positively affect market growth during the forecast period.  

Key Players

  • Bio-Rad Laboratories, Inc. (US)
  • Danaher Corporation (US)
  • Thermo Fisher Scientific, Inc. (US)
  • Miltenyi Biotec (Germany)
  • Merck KGAA (Germany)
  • Qsonica, LLC (US)
  • Becton Dickinson & Company (US)
  • Cell Signaling Technology, Inc. (US)
  • Hoffmann–La Roche Ltd (Switzerland)
  • Qiagen N.V. (Netherlands)

Segmentation

The global Cell Lysis & Disruption Market has been segmented into technique, product, cell type, and end user.

By technique, the market has been segregated into reagent based and physical disruption. The reagent based segment has been further sub-segmented into detergent and enzymatic. The physical disruption further divided into mechanical homogenization, ultrasonic homogenization, pressure homogenization, and temperature treatments

By product, the market has been bifurcated into consumables and instruments. The consumables segment is estimated to hold major market share in the market due to the rise in funding of cell based research. Consumables has been further divided into reagent and kits, beads and disposables. The instrument segment has been further categorized as sonicators, homogenizers, French press, microfluidizer, and others. 

On the basis of cell type, the global cell lysis & disruption market has been classified as mammalian cells, microbial cells, and others.

The global cell lysis & disruption market, by end user, has been divided into research laboratories and institutes, pharmaceutical and biotechnology companies, and others.

Regional Analysis

On a regional basis, the Americas is anticipated to dominate the global cell lysis & disruption market owing to the growing clinical R&D budgets by both governments as well as public and private organizations in the pharmaceutical and biotech sector and increasing demand for novel therapeutics in the region.  Additionally, the rising prevalence of geriatric population along with various chronic diseases is contributing to the growth of this market.

According to a report by the Population Reference Bureau, the number of older population (aged 65 and above) will rise to nearly 24% from 15% by 2060. Europe is expected to hold the second-largest position in the global cell lysis & disruption cell lysis buffer market owing to the presence of a strong academic & research base and availability of funding for research in the European countries. Moreover, rising healthcare expenditure is boosting the market in this region. Asia-Pacific is anticipated to be the fastest-growing region is due to the growing interest of major key players in emerging markets and rapidly developing healthcare infrastructure in this region. The Middle East & Africa has the least share of the global cell lysis & disruption market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the healthcare sector. 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013v

Immunoprecipitation Market SWOT Analysis, Major Key Players Revenue, Analysis and Forecasts to 2027

 Market Analysis

The global immunoprecipitation market is predicted to touch USD 562 million at a 5.2% CAGR over the forecast period (2022-2027), states the new Market Research Future (MRFR) report. Immunoprecipitation (IP), simply put, is a technique to precipitate a protein antigen out of a solution utilizing an antibody which specifically binds to that specific protein. The process can be used for isolating and concentrating a specific protein from a sample having thousands of various proteins. The IP technique help researchers in identifying the proteins activation status, determining protein modifications that are post-translational, measuring a given protein’s molecular weight, and capturing protein-binding molecules in both the study of protein-nucleic and protein-protein interactions.

Various factors are propelling the immunoprecipitation market growth. These factors, as per the new MRFR report, include increasing number of research activities in life science, growing need for identifying antigens related to autoimmune diseases, and increasing investments by industries and governments. Additional factors pushing market report include growing awareness regarding personalized therapeutics, rising biotechnology research, a growing number of immunoprecipitation assays to purify and isolate antigens, and repeat purchase of kits.

On the flip side, the availability of alternative protein purification technologies may hamper the immunoprecipitation market growth over the forecast period.

Key Players

Leading players profiled in the immunoprecipitation market report include Geno Technology Inc., Cell Signaling Technology, Inc., Rockland Immunochemicals Inc., Takara Bio Inc., BioLegend, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, and Abcam plc, GenScript. Various strategies have been adopted by key players for capturing the competitive market such as partnerships, collaborations, mergers and acquisitions, research and development activities, and more.

April 2022: EpiCypher has signed an agreement with Thermo Fisher Scientific to offer co-exclusive usage of SNAP ChiP (sample normalization and antibody profiling for chromatin immunoprecipitation) technology that is specific for histone PTMS.

Market Segmentation

The MRFR report provides an all-inclusive segmental analysis of the Immunoprecipitation Market report on the basis of product, type, and end user.

Based on type, the immunoprecipitation market is segmented into RNA immunoprecipitation, chromatin immunoprecipitation, co-immunoprecipitation, and individual immunoprecipitation. Of these, the individual immunoprecipitation segment will have the largest share in the market over the forecast period. The individual immunoprecipitation is widely used to study protein-protein interactions for detecting the presence of antigens and determining its relative quantity that is driving its use in different research studies.

Based on product, the immunoprecipitation market is segmented into reagent, kit, and others. The reagent segment is again segmented into beads and antibodies. Antibodies are again segmented into primary as well as secondary. Beads are again segmented into buffers, magnetic beads, and agarose beads. Of these, the agarose beads segment will dominate the market over the forecast period.

Based on end user, the immunoprecipitation market is segmented into contract research organizations, academic and research institutes, pharmaceutical and biotechnology companies, and others. Of these, the pharmaceutical and biotechnology companies segment will lead the market over the forecast period chiefly due to the growing demand for protein-based drugs.

Regional Analysis

By region, the immunoprecipitation market report covers the latest trends and growth opportunities across the Americas, Europe, the Asia Pacific, and the Middle East and Africa. Of these, the Americas will lead the market over the forecast period. Factors aiding growth in the region include the presence of several market players, increasing research activities, and a well-developed healthcare sector in the region.

The immunoprecipitation market in Europe is predicted to have the second-largest share in the market over the forecast period. This is chiefly due to the accessibility of funds for research.

The immunoprecipitation market in the APAC region is predicted to grow at the fastest pace over the forecast period. Factors aiding growth in the region include growing awareness regarding personalized therapeutics, growing biotechnology research in the region, and growing investment from governments.

The immunoprecipitation market in the Middle East and Africa is predicted to have a small share in the market over the forecast period.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013v

Hemostasis and Tissue Sealing Agents Market Financial Overview, SWOT Analysis, Key Development and Forecasts Till 2027

 Market Highlights

The global hemostasis and tissue sealing agents market is projected to grow at a CAGR of 8.6% over the forecast period. There has been increasing demand for such products as it reduces complication during surgical procedures. Moreover, large number of surgical procedures across the globe are impacting the growth of the market positively. Increasing numbers of surgery procedures worldwide is one of another reason for driving the growth of the hemostasis and tissue sealing agents market.  Surgeries are performed by making cut on the body which leads to the wound formation. Hemostasis and tissue sealing agents products are used in external surgical processes for reducing bleeding. For example, they are used in neurosurgical procedures, cardiac surgery, bariatric surgery, leg surgery, cesarean and orthopedic surgery. Hemostasis and tissue sealing agents products, are frequently used to reduce complexity and reduce recovery time after surgery. The high surgical procedure numbers lead to rising need for hemostasis and tissue sealing agents which reduces the risk during surgical procedures. However, factors such as increasing advancement minimally invasive procedures, lack of reimbursement for these products is hampering the growth of the market.

Key Players

Some of the prominent players in the global hemostasis and tissue sealing agents market are Johnson & Johnson, Cryolife, Inc., Baxter International, Inc, Ethicon LLC, Integra Lifesciences Corporation, Becton, Dickinson & Company, Cohera Medical, Inc., Pfizer, Inc, Medtronic plc, B. Braun Melsungen AG, MIL Laboratories Pvt. Ltd, Advanced Medical Solutions Group Plc and others.

Segmentation

The global hemostasis and tissue sealing agents market has been segmented into product, and end user.

By product, the market has been segmented into topical hemostats, and adhesive & tissue sealant. Furthermore, topical hemostats is divided into Active, mechanical (collagen based hemostats, cellulose based hemostats, gelatin based hemostats, polysaccharide based hemostats) Flowable. Adhesive & tissue sealant is further segmented into synthetic, natural, and adhesion barrier.

Further on the basis of end user the market is bifurcated into hospitals, ambulatory centers and others

Regional Analysis

Geographically, the Americas is anticipated to dominate the global hemostatic agent market owing to the high clinical R&D budgets by both government as well as public and private organizations, presence of major manufacturers for the products, high number of surgical procedures and various others. For instance, according to the Center for Diseases Control and Prevention, approximately 46.5 million surgical procedures are performed every year in the U.S.

Europe is expected to hold the second largest position in the global hemostasis and tissue sealing agents market. The Hemostasis and tissue sealing agents market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increased medical tourism for surgical procedures, increasing healthcare expenditure in developing countries and various others. The Middle East & Africa has the lowest share of the global hemostasis and tissue sealing agents market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013v

Assisted Reproductive Technology Market Solid Segment Analyzed by Latest Trends, Growth Rate and 2027 Insight

 Market Highlights

The assisted reproductive technology (ART) market is expected to witness tremendous growth owing to the rising prevalence of infertility in males as well as females. Other key factors such as the growing obesity among population, rising ovulation disorders, change to sedentary lifestyle, socioeconomic factors like postponement of marriage due to unemployment and others, growing consumption of unhealthy diet, increasing occurrence of polycystic ovarian syndrome (PCOS), and increasing prevalence of breast or ovarian and endometrial cancer, increase in smoking and alcohol consumption are contributing towards the growth. 

However, factors such as, lower success rate, the high cost of artificial reproductive technology procedures, expensive treatments, raising ethical issues, chances of birth defects, the risk of prematurity and low birth weight in new-borns and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.

Key Players

Some of the key players in the global assisted reproductive technology (ART) market are Cosmos Biomedical Limited, California Cryobank, Bloom IVF Centre, Cryolab Ltd., Parallabs, OvaScience, Anecova, Origio, Microm Ltd., Merck KGaA, Cooper Surgical, Inc, Ferring Pharmaceuticals, European Sperm Bank, Irvine Scientific and Hamilton Throne Ltd.

Segmentation

The global Assisted Reproductive Technology Market is segmented on the basis of diagnosis, type, and end-user. The assisted reproductive technology market, by diagnosis, is categorized into ovulation testing, hysterosalpingography, ovarian reserve testing, genetic testing, other hormone testing and imaging tests. On the basis of type, the market is segmented into Ovulation Induction (OI), Artificial Insemination (AI), Donor Conception, In-Vitro Fertilization (IVF), Gamete Intrafallopian Transfer (GIFT), Intracytoplasmic Sperm Injection (ICSI), Preimplantation Genetic Diagnosis (PGD) and Surrogacy. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and IVF Centers and others

Regional Analysis

Europe (UK, Belgium, France, and Netherlands) is the largest in the market owing to the increasing prevalence of obesity and growing healthcare expenditure. As per the World Health Organization, 23% of the women in Europe were obese in 2014.

The Americas is the second largest the assisted reproductive technology (ART) market during the forecast period. The increasing occurrence of ovarian cancer drives the market in this region. The American Cancer Society estimated that in 2018, 22,240 women are likely to be diagnosed with ovarian cancer. This is expected to influence the market growth during the forecast period. 

Asia-Pacific was projected to be the fastest growing region for the global assisted reproductive technology (ART) market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. According to the Virtus Health 2018, infertility affects one in six Australian couples of the reproductive age. This is expected to provide favorable backgrounds for the market to grow.

The Middle East and Africa accounts for the least share due to stringent government policies and low per capita income.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013v

Clinical Decision Support Systems Market Value Chain, Factor Analysis, Region and Forecasts Till 2027

 Market Overview:

With a 12 percent CAGR, the Clinical Decision Support Systems (CDSS) market is estimated to reach USD 1.76 billion by 2023. Clinical decision support systems (CDSS) are an essential component of the healthcare IT spectrum. Breakthrough technological developments encourage CDSS adoption, which enables speedier decision-making, data management, and enhanced workflow competency in inpatient care. The adjustable functions of this system are playing a significant role in boosting Clinical Decision Support Systems Market trends. The COVID-19 epidemic has created new hurdles in the healthcare ecosystem. Hospitals and health systems are dealing with massive influxes of critically sick patients as well as personnel shortages and capacity constraints.

However, doctors are now better equipped with the information and abilities gained during the pandemic's early stages to develop the ideas. The increased usage of clinical decision support software in COVID-19 has emphasized the global need for comparable healthcare data while shortening the duration of decision-making owing to unprecedented stress. Many health care providers have changed their clinical decision support system vendors to promptly communicate desired outcomes. As a result, many of the world's major healthcare facilities, which are among the first responders, have a greater understanding of the usefulness and challenges of clinical decision support systems to discover new ideas for the company and for the future market. As a result, there is a need for clinical decision assistance in forms that make pertinent data easily accessible. Workflow integration is expected to emphasize market expansion in the future.

Competitive Landscape

Some of the key players in the global clinical decision support system are Meditech, Cerner Corporation, Carestream, Elsevier B.V., Wolters Kluwer Health, Agfa-Gevaert Group, Athenahealth, Inc, Epic Systems Corporation, Allscripts, Hearst health and others.

Market Segmentation:

It is expected that the software segment will grow rapidly.

By Product: During the projection period, the integrated variant category is expected to gain traction.

By knowledge: The knowledge-based CDSS is expected to acquire market share as a result of increased efficiency in fast-paced workplaces. The cloud sector has more potential since it provides more scalability throughout the predicted period.

Regional Classification:

Because of the region's cutting-edge healthcare computerised decision support system industry, North American clinical decision support businesses are expected to lead the worldwide market. The technical advancement in the healthcare industry in North America has been consistent due to the presence of several key firms in the region, resulting in access to various progressive models of clinical decision support systems. The region's rising healthcare expenditure is expected to drive the clinical decision support systems market in the future.

Industry News:

The clinical decision support systems market is dominated by some competitors worldwide. The Americas is a significant company's center, earning maximum market share and transforming this area into a well-established market. These firms have also extended their operational units to other locations. Furthermore, additional small and medium-sized firms profit from the local market. Wolters Kluwer Health, Allscripts, Meditech, Athenahealth, Inc, Cerner Corporation, Elsevier B.V., Hearst Health, Carestream, Epic Systems Corporation, and Agfa-Gevaert Group are important competitors in the worldwide clinical decision support system market. In 2017, the top four businesses were Meditech, Cerner Corporation, Epic Systems Corporation, and Allscripts, which accounted for almost 60% of the overall clinical decision support systems market.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013v

Blood Glucose Monitoring Market SWOT Analysis, Major Key Players Revenue, Analysis and Forecasts to 2027

 Blood Glucose Monitoring Market Overview:

A healthy body stays healthy due to all kinds of enzymes in the body being in proper balance. Excess of an enzyme can disturb balance while deficiency of another one can have the same effect. People who are suffering from genetic ailments like diabetes are more prone to such problems. Therefore, monitoring things like glucose in the blood is necessary for such people, and this is the reason for the global blood glucose monitoring market to take shape and grow. Blood glucose monitoring helps to recognize the glucose level of blood within the specified target range. The devices facilitating this monitoring provide useful insight to manage diabetes. These insights help to track the progress of treatment goal and observe the effect of medication on blood sugar level and understand how the ailment affects glucose level in blood.

Market Research Future (MRFR) has published a research report about the global blood glucose monitoring market that predicts the market growth with 7.1 % CAGR (Compound Annual Growth Rate) between 2017 and 2023. Devices known as blood glucose meter are designed to apply to the different type of diabetes. According to this report, the market for these devices is growing due to developing technology for monitoring and diagnosis of diabetes, early detection of diabetes, increasing demand for continuous glucose monitoring devices, and increasing prevalence of diabetes.

Key Players

The key players in the global blood glucose monitoring market include Abbott Laboratories (USA), Arkay, Inc. (the USA), Bayer Healthcare AG (Germany), Dexcom, Inc. (the USA), GlySure Ltd (UK), Goldsite Diagnostics Inc. (China), F. Hoffmann-La Roche Ltd (Switzerland), LifeScan, Inc. (the USA), and Sphere Medical Holding PLC (UK).

Segmentations:

In this report, the global Blood Glucose Monitoring Market has been segmented on the basis of application, end user, product type, and lastly, region. On the basis of application, this market has been segmented into type 1 diabetes, type 2 diabetes, gestational diabetes, and others. The first two types of diabetes harm the body in the same way. The difference between the first two types of diabetes is regarding insulin. Patients suffering from type 1 diabetes do not produce insulin. On the other hand, patients with type 2 diabetes do not respond to insulin as well as they should and later in the disease often do not make enough insulin. Their body produces a little bit of insulin but fails to use it effectively. Gestational diabetes only happens during pregnancy. The patient gets high blood sugar levels during pregnancy, despite their levels being normal before pregnancy.

On the basis of product type, the market has been segmented into continuous glucose monitoring (CGM), invasive glucose monitoring (IGM), and flash glucose monitoring. CGM is defined as an advanced way for people living with diabetes to check glucose readings in real-time or monitor them over a period of time. IGM refers to the measurement of blood glucose levels (required by people with diabetes to prevent both acute and chronic complications from the disease) by taking their blood sample. Flash Glucose Monitoring is a small sensor that diabetes patient wears on the skin. This sensor stores the user's blood glucose (or blood sugar) levels continuously. The user can access them by scanning the sensor at his/her ease. Based on end users, the market has been segmented into clinics, diagnostic centers, home care diagnostics, hospitals, and research centers.

Regional Analysis:

The regional segmentation of global Blood Glucose Monitoring Market Growth segments the market into regions namely The Americas (North America & South America), Europe, Asia Pacific, and Middle East & Africa (MEA). The Americas command the largest market share due to the notable increasing incidence of obesity, physical inactivity, and unhealthy diet. With medical facilities being more advanced in North America, it is a bigger market than South America. In North America, the biggest markets comprise of the United States of America (USA) and Canada. Many key players in this market are based in the USA.

Due to reasons same as The Americas, in Europe, Western Europe is greater market than Eastern Europe. Europe is the second largest market for blood glucose monitoring, followed by the Asia Pacific in the global blood glucose monitoring market, owing to the environmental pollutants, psychosocial factors, smoking, and socioeconomic deprivation. Furthermore, government support via for research & development (R & D) regarding blood glucose monitoring boosts this market. The biggest markets in Europe, include France, Germany, Italy, Spain, and the United Kingdom (UK), followed by the rest of Europe.

In the Asia Pacific region, the market is growing rapidly due to high population and increasing number of diabetes patients. In this region, people are not as health conscious as they are in North America and Europe. Due to increasing demand for new treatment methods in countries like India and South Korea, Asia Pacific is likely to emerge as the fastest growing market across the globe during the forecast period. Apart from India and South Korea, the biggest markets in this region include Australia and Japan, followed by the rest of Asia Pacific.

In the MEA region, the market is small and limited due to little investment in healthcare and lack of awareness about health problems. In this region, the biggest market comprises of Kuwait, Oman

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013v

Growth Hormone Deficiency Market 2022 Estimation and Forecasts up to 2027

  Growth Hormone Deficiency Market Growth hormone deficiency also called pituitary dwarfism or simply dwarfism, refers to a condition result...